第48届圣安东尼奥乳腺癌研讨会（SABCS 2025）将于当地时间2025年12月9-12日在美国得克萨斯州圣安东尼奥Henry B.Gonzalez Convention Center举行。作为乳腺癌领域的顶级盛会，SABCS聚焦乳腺癌生物学、病因、预防、诊断及治疗前沿，促进临床、转化与基础研究的深度融合，为全球科研人员提供交流协作与专业成长的平台。肿瘤瞭望-乳腺时讯特将会议第四天（12月12日）内容进行梳理，并将全体大会3（General Session 3）及Mini口头报告（Rapid Fire 5）题目进行整理，以飨读者，敬请持续关注后续报道！
编者按：第48届圣安东尼奥乳腺癌研讨会（SABCS 2025）将于当地时间2025年12月9-12日在美国得克萨斯州圣安东尼奥Henry B.Gonzalez Convention Center举行。作为乳腺癌领域的顶级盛会，SABCS聚焦乳腺癌生物学、病因、预防、诊断及治疗前沿，促进临床、转化与基础研究的深度融合，为全球科研人员提供交流协作与专业成长的平台。肿瘤瞭望-乳腺时讯特将会议第四天（12月12日）内容进行梳理，并将全体大会3（General Session 3）及Mini口头报告（Rapid Fire 5）题目进行整理，以飨读者，敬请持续关注后续报道！
四场海报聚焦专场：1、海报聚焦10：内分泌治疗的新型联合方案；2、海报聚焦11：人工智能在病理学与风险分层中的应用；3、海报聚焦12：当代局部区域治疗挑战：降阶梯治疗时机探讨；4、海报聚焦13：聚焦中枢神经系统肿瘤。
一场大会特邀讲座：BRCA1/2肿瘤发生的遗传和表观遗传决定因素
一场全体大会专场：全体大会3。
一场海报展示：Poster Session 5
一场Mini口头报告：Rapid Fire 5
三场特殊专场：1、超越癌症：处理治疗后的身体形象、脱发和皮肤健康问题；2、年度回顾；3、一线实战指南：周一清晨的肿瘤诊疗策略。
一场颁奖讲座：AACR乳腺癌研究杰出研究者奖
一场辩论：是否所有早期乳腺癌患者都需要腋窝分期
专场：General Session 3
时间：12月12日9:00 AM–11:30 AM CST
地点：Hall 1
摘要号：GS3-01
Menopausal Hormone Therapy and the Risk of Breast Cancer in Women with a Pathogenic Variant in BRCA1 or BRCA2
携带BRCA1或BRCA2致病性变异的女性接受绝经后激素治疗与乳腺癌风险的关系
讲者：Joanne Kotsopoulos，Women’s College Hospital，Toronto，ON，Canada
摘要号：GS3-02
Fertility and ovarian function preservation in premenopausal women with early breast cancer:results from the multicenter prospective PREgnancy and FERtility(PREFER)study
绝经前早期乳腺癌女性患者的生育能力及卵巢功能保护：多中心前瞻性PREgnancy和FERtility（PREFER，即妊娠与生育）研究的结果
讲者：Matteo Lambertini，University of Genova–IRCCS Ospedale Policlinico San Martino，Genoa，Italy
摘要号：GS3-03
Randomized controlled trial of Young，Empowered&Strong(YES)，an mHealth intervention for adolescent and young adult breast cancer survivors
针对青少年和年轻成年乳腺癌幸存者的移动健康干预——Young，Empowered&Strong(YES)的随机对照试验
讲者：Ann H Partridge，Dana-Farber Cancer Institute，Boston，MA
摘要号：GS3-04
Effects of Acupuncture vs Sham Acupuncture and Usual Care on Cancer-Related Cognitive Difficulties Among Breast Cancer Survivors:The ENHANCE Randomized Clinical Trial
针刺与假针刺及常规护理对乳腺癌幸存者癌症相关认知障碍的影响：ENHANCE随机临床试验结果
讲者：Jun Mao，Memorial Sloan Kettering Cancer Center，New York，NY
摘要号：GS3-05
Evaluation of the Sensitivity to Endocrine Therapy(SETER/PR)assay to predict benefit from extended endocrine therapy in the NRG/NSABP B-42 trial
在NRG/NSABP B-42试验中评估对内分泌治疗的敏感性（SETER/PR）检测来预测延长内分泌治疗的获益
讲者：Eleftherios P Mamounas，AdventHealth Cancer Institute，Orlando，FL
摘要号：GS3-06
Rb Functions as a Transcriptional Activator of ER Targets Following CDK4/6 Inhibition in Luminal Breast Cancer
在Luminal型乳腺癌中，Rb在CDK4/6抑制后作为ER靶点的转录激活因子发挥作用
讲者：April C Watt，Peter MacCallum Cancer Centre，Melbourne，Australia
摘要号：GS3-07
Risk-based breast cancer screening is safe，preferred by women and identifies highest risk individuals:Results from WISDOM 1.0
基于风险的乳腺癌筛查是安全的，是女性的首选，并可识别最高风险个体：WISDOM 1.0的结果
讲者：Laura J Esserman，UCSF，San Francisco，CA
摘要号：GS3-08
Imlunestrant with or without abemaciclib in advanced breast cancer(ABC):Updated efficacy results from the phase 3 EMBER-3 trial
免疫抑制剂联合或不联合阿贝西利治疗晚期乳腺癌（ABC）：3期EMBER-3研究的最新疗效结果
讲者：Komal L Jhaveri，Memorial Sloan Kettering Cancer Center，New York，NY
摘要号：GS3-09
Clinical and biomarker subgroup analysis of evERA Breast Cancer:A Phase III trial of giredestrant plus everolimus in patients with estrogen receptor-positive，HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor
evERA乳腺癌的临床和生物标志物亚组分析：girestrant联合依维莫司治疗既往接受过CDK4/6抑制剂治疗的ER+/HER2-晚期乳腺癌患者的一项III期试验
讲者：Hope S Rugo，City of Hope Comprehensive Cancer Center，Duarte，CA
摘要号：GS3-10
Expanding Therapeutic Options in Hormone Receptor Positive Metastatic Breast Cancer
扩大激素受体阳性转移性乳腺癌的治疗选择
讲者：Nicholas Turner，Institute of Cancer Research，London，United Kingdom
专场：Rapid Fire 5
时间：12月12日12:30 PM–1:30 PM CST
地点：Stars at Night 1-2
摘要号：RF5-01
Cancer-specific risks associated with germline PALB2 pathogenic variants from a large clinical genetic testing cohort
来自大型临床基因检测队列的与生殖细胞系PALB2致病变异体相关的癌症特异性风险
讲者：Yen Y.Tan，Medical University of Vienna，Vienna，Austria
摘要号：RF5-02
Tbcrc 056:a phase 2 study of neoadjuvant niraparib with dostarlimab for patients with BRCA-or PALB2-mutated breast cancer:results from the TNBC cohorts
Tbcrc 056：尼拉帕利联合dostarlimab新辅助治疗BRCA或PALB2突变乳腺癌患者的2期研究：来自TNBC队列的结果
讲者：Erica L Mayer，Dana-Farber Cancer Institute，Boston，MA
摘要号：RF5-03
Olympian:a phase 2，multicenter，open-label study to assess the efficacy and safety of neoadjuvant olaparib monotherapy and olaparib plus durvalumab in patients with brca mutations and early-stage her2-negative breast cancer
Olympian研究：一项评估新辅助奥拉帕利单药治疗及奥拉帕利联合度伐利尤单抗在BRCA突变早期HER2阴性乳腺癌患者中的疗效和安全性的2期、多中心、开放性研究
讲者：Nadine Tung，Beth Israel Deaconess Medical Center，Dana-Farber Harvard Cancer Center，Boston，MA
摘要号：RF5-04
Germline pathogenic variants in the personalized screening arm of the WISDOM Study:Findings from 23，098 women with no personal history of breast cancer
WISDOM研究中个性化筛查组的种系致病性变异：对23098名无乳腺癌个人史女性的研究结果
讲者：Kirkpatrick B.Fergus，University of California San Francisco，San Francisco，CA
摘要号：RF5-05
Predicting olaparib sensitivity in patients with metastatic HER2-negative breast cancer with BRCA1/2，PALB2，RAD51C/D mutations according to their homologous recombination status by the RAD51 test:Primary analysis of the RADIOLA phase II trial
根据RAD51检测的同源重组状态，预测有BRCA1/2、PALB2、RAD51C/D突变的转移性HER2阴性乳腺癌患者对奥拉帕利的敏感性：RADIOLA 2期研究的主要分析
讲者：Isabel Pimentel，Vall d’Hebron University Hospital/Vall d’Hebron Institute of Oncology(VHIO)，Barcelona，Spain
摘要号：RF5-06
Pathologic complete response rates(pCR)after the novel HER2 ADC ARX788:Results from the I-SPY2.2 trial
新型HER2 ADC ARX788治疗后的病理完全缓解率（pCR）：I-SPY2.2研究的结果
讲者：Paula R Pohlmann，University of Texas MD Anderson Cancer Center，Houston，TX
京公网安备 11010502033352号